

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

1. Name and Address of Reporting Person* <u>TVM V LIFE SCIENCE VENTURES GMBH & CO KG</u> (Last) (First) (Middle) <u>C/O TVM CAPITAL CROUP</u> <u>OTTOSTRASSE 4</u> (Street) <u>MUNICH 2M 80333</u> (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>ENANTA PHARMACEUTICALS INC [ENTA]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) <u>02/18/2014</u>	
4. If Amendment, Date of Original Filed (Month/Day/Year)		

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	02/18/2014		S		1,546	D	\$40.1853 ⁽¹⁾	389,835	D ⁽²⁾	
Common Stock	02/18/2014		S		2,066	D	\$40.1853 ⁽¹⁾	520,978	D ⁽³⁾	
Common Stock	02/18/2014		S		6,388	D	\$40.1853 ⁽¹⁾	1,611,306	D ⁽⁴⁾	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)					

1. Name and Address of Reporting Person*
TVM V LIFE SCIENCE VENTURES GMBH & CO KG
 (Last) (First) (Middle)
C/O TVM CAPITAL CROUP
OTTOSTRASSE 4
 (Street)
MUNICH 2M 80333
 (City) (State) (Zip)

1. Name and Address of Reporting Person*
TVM V Life Science Ventures Management GmbH & Co. KG
 (Last) (First) (Middle)
C/O TVM CAPITAL GROUP
OTTOSTRASSE 4
 (Street)
MUNICH 2M 80333
 (City) (State) (Zip)

1. Name and Address of Reporting Person*

[TVM IV GMBH & CO KG](#)

(Last) (First) (Middle)

C/O TVM CAPITAL GROUP

OTTOSTRASSE 4

(Street)

MUNICH 2M 80333

(City) (State) (Zip)

1. Name and Address of Reporting Person*

[TVM IV Management GmbH & Co. KG](#)

(Last) (First) (Middle)

C/O TVM CAPITAL GROUP

OTTOSTRASSE 4

(Street)

MUNICH 2M 80333

(City) (State) (Zip)

1. Name and Address of Reporting Person*

[TVM MEDICAL VENTURES GMBH & CO KG](#)

(Last) (First) (Middle)

C/O TVM CAPITAL GROUP

OTTOSTRASSE 4

(Street)

MUNICH 2M 80333

(City) (State) (Zip)

1. Name and Address of Reporting Person*

[TVM Capital GmbH](#)

(Last) (First) (Middle)

C/O TVM CAPITAL GROUP

OTTOSTRASSE 4

(Street)

MUNICH 2M 80333

(City) (State) (Zip)

1. Name and Address of Reporting Person*

[Birner Hubert](#)

(Last) (First) (Middle)

C/O TVM CAPITAL GROUP

OTTOSTRASSE 4

(Street)

MUNICH 2M 80333

(City) (State) (Zip)

1. Name and Address of Reporting Person*

[Fischer Stefan](#)

(Last) (First) (Middle)

C/O TVM CAPITAL GROUP

OTTOSTRASSE 4

(Street)

MUNICH	2M	80333
(City)	(State)	(Zip)
1. Name and Address of Reporting Person *		
Goll Alexandra		
(Last)	(First)	(Middle)
C/O TVM CAPITAL GROUP		
OTTOSTRASSE 4		
(Street)		
MUNICH	2M	80333
(City)	(State)	(Zip)

Explanation of Responses:

- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$40.00 to \$40.78, inclusive. Each Reporting Person undertakes to provide to Enanta Pharmaceuticals, Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission ("SEC"), upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- The shares are directly held by TVM Medical Ventures GmbH & Co. KG ("Medical Ventures"), the general partner of which is TVM Capital GmbH ("TVM Capital"), for which Alexandra Goll ("Goll"), one member of the investment committee of TVM Capital, shares voting and investment authority over the shares held by Medical Ventures with the other member of the investment committee. Each of TVM Capital and Goll disclaims beneficial ownership of these shares except to the extent of their pecuniary interest therein, if any.
- The shares are directly held by TVM IV GmbH & Co. KG ("TVM IV"), the managing limited partner of which is TVM IV Management GmbH & Co. KG ("TVM IV Management"), for which Goll, one member of the investment committee of TVM IV Management, shares voting and investment authority over the shares held by TVM IV with the other members of the investment committee. Each of TVM IV Management and Goll disclaims beneficial ownership of these shares except to the extent of their pecuniary interest therein, if any.
- The shares are directly held by TVM V Life Science Ventures GmbH & Co. KG ("TVM V"), the managing limited partner of which is TVM V Life Science Ventures Management GmbH & Co. KG ("TVM V Management"), for which Hubert Birner ("Birner"), Stefan Fischer ("Fischer") and Goll, each a member of the investment committee of TVM V Management, shares voting and investment authority over the shares held by TVM V. Each of TVM V Management, Birner, Fischer and Goll disclaims beneficial ownership of these shares except to the extent of their pecuniary interest therein, if any.

Remarks:

[/s/ Josef Moosholzer,
Managing Limited Partner of
TVM V Life Science Ventures
Management GmbH & Co. KG, managing limited partner
of TVM V Life Science
Ventures GmbH & Co. KG](#) [02/20/2014](#)

[/s/ Josef Moosholzer,
Managing Limited Partner of
TVM V Life Science Ventures
Management GmbH & Co. KG](#) [02/20/2014](#)

[/s/ Josef Moosholzer,
Managing Limited Partner of
TVM IV Mangement GmbH &
Co. KG, managing limited
partner of TVM IV GmbH &
Co. KG](#) [02/20/2014](#)

[/s/ Josef Moosholzer,
Managing Limited Partner of
TVM IV Mangement GmbH &
Co. KG](#) [02/20/2014](#)

[/s/ Josef Moosholzer,
Managing Limited Partner of
TVM Capital GmbH, general
partner of TVM Medical
Ventures GmbH & Co. KG](#) [02/20/2014](#)

[/s/ Josef Moosholzer,
Managing Limited Partner of
TVM Capital GmbH](#) [02/20/2014](#)

[/s/ Rolf Starck by power of
Attorney for Hubert Birner](#) [02/20/2014](#)

[/s/ Rolf Starck by power of
Attorney for Stefan Fischer](#) [02/20/2014](#)

[/s/ Rolf Starck by power of
Attorney for Alexandra Goll](#) [02/20/2014](#)

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.